Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2123473 | 0.88 | KMT2A (0.58) | CXCR4MEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL1637100 | 0.86 | CXCR4 (0.72) | CXCR4MEN1KMT2ATAAR1TSHR | |
| SCHEMBL1637273 | 0.86 | CXCR4 (0.72) | CXCR4MEN1KMT2ATAAR1TSHR | |
| SCHEMBL1637097 | 0.86 | CXCR4 (0.72) | CXCR4MEN1KMT2ATAAR1TSHR | |
| SCHEMBL2127047 | 0.86 | CYP2D6 (0.46) | CXCR4TAAR1TSHRCYP2D6LMNA | |
| SCHEMBL13785302 | 0.84 | CXCR4 (0.64) | CXCR4MEN1KMT2ATAAR1TSHR | |
| SCHEMBL1636462 | 0.83 | CXCR4 (0.70) | CXCR4MEN1KMT2ATAAR1TSHR | |
| SCHEMBL1636460 | 0.83 | CXCR4 (0.70) | CXCR4MEN1KMT2ATAAR1TSHR | |
| SCHEMBL1637422 | 0.82 | CXCR4 (0.85) | CXCR4TAAR1 | |
| SCHEMBL1637905 | 0.81 | CXCR4 (0.76) | CXCR4TAAR1TSHRCYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1724263-B1 | BASIC AMINE COMPOUND AND USE THEREOF | KUREHA CORP (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | KUREHA CORPORATION (JP) | 2011-07-14 | — | — | US | disclosed |
| US-7932281-B2 | Amine-based compound and use thereof | KUREHA CORPORATION (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1724263-A1 | BASIC AMINE COMPOUND AND USE THEREOF | Kureha Corporation (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | NR0B2, NR5A2, NR1D2 | CXCR4 86/4885MEN1 1008/4885KMT2A 474/4885 |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | NR0B2, NR5A2, NR2E1 | CXCR4 100/4885MEN1 1361/4885KMT2A 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.